Tags : Hormone-Sensitive Prostate Cancer

Janssen Receives EC’s Approval for Expanded Use of Erleada (apalutamide)

Tuba Khan January 30, 2020

Shots: The EC’s approval is based on P-III TITAN study assessing Erleada + ADT vs PBO + ADT in 1052 patients in a ratio (1:1) with mHSPC regardless of the […]readmore

Tags : Hormone-Sensitive Prostate Cancer

Janssen Receives EC’s Approval for Expanded Use of Erleada (apalutamide)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Hormone-Sensitive Prostate Cancer

Janssen Receives EC’s Approval for Expanded Use of Erleada (apalutamide)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company